ICIs are increasingly being used in the management of oncologic conditions. Although it provides an effective treatment option with the opportunity for long-term positive outcomes, it has the potential for autoimmune toxicities with a variable and prolonged time course. Tune in to hear how the pharmacist can play a key role in imAE management in patients receiving ICIs.

The Topic of Episode 12: Immune Checkpoint Inhibitor (ICI) Management.

Learning Objectives:

• Summarize the spectrum of immune mediated adverse events (imAE) with ICIs and apply management principles using the five pillars of imAE management
• Discuss challenges with identification and management of imAEs with combination therapy such as ICI + TKIs
• Review clinically relevant pharmacodynamic drug interactions with ICIs and with practical management tips
• Describe the role of the pharmacist in caring for patients receiving ICIs

Glenn Myers is a pharmacist with a focus in outpatient medical oncology at the Dr. Sheldon H Rubin Oncology Clinic in Moncton, New Brunswick. Glenn completed a BSc (Pharmacy) at Dalhousie University in 2011 and subsequently went on to complete his hospital residency at the Saint John Regional Hospital in New Brunswick. Glenn has been practicing in ambulatory oncology for over 10 years and focuses on clinical assessment and management of chemotherapy, oral anti-cancer and immune related adverse effects in patients with cancer. Glenn maintains an active role as the chair of the sponsorship committee with the Canadian Association of Pharmacy in Oncology (CAPhO). Glenn’s other professional interests include teaching and mentoring various levels of pharmacy learners, providing practical education to healthcare professionals, working with retail pharmacies to improve oncology patient care in the community, and performing oncology pharmacy practice-based research to advance the scope of oncology pharmacy.